-
Innovation Ranking
Innovation Ranking – TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Envafolimab in Pleomorphic Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Envafolimab in Pleomorphic Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Envafolimab in Pleomorphic Liposarcoma Drug Details: Envafolimab (Enweida) is a recombinant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Envafolimab in Fibrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Envafolimab in Fibrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Envafolimab in Fibrosarcoma Drug Details: Envafolimab (Enweida) is a recombinant humanized single...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Envafolimab in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Envafolimab in Soft Tissue Sarcoma Drug Details: Envafolimab (Enweida) is a recombinant humanized single domain...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Liposarcoma - Drugs In Development, 2023’, provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of...
-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pleomorphic Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pleomorphic Liposarcoma - Drugs In Development, 2023’, provides an overview of the Pleomorphic Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pleomorphic Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: TRACON Pharmaceuticals Inc’s Methoxyamine Hydrochloride
Empower your strategies with our Net Present Value Model: TRACON Pharmaceuticals Inc's Methoxyamine Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Vulvar Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Vulvar Cancer Drug Details: XmAb-717 is under development for the treatment of cervical...